1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach

 
• By Eleanor Malone

Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.

Security office center. Turnstile with card reader. Electronic checkpoint with a turnstile in the office center. Turnstile spinner. - Image
Technology aims to stop macrophage docking to cancer cell

MorphoSys AG plans to explore the potential for combining a new class of oral small-molecule compounds targeting the QPCTL enzyme with its own Phase II/III anti-CD19 antibody tafasitamab (MOR208), which is in development for the treatment of lymphoma. It has obtained an exclusive option to license the compounds in the field of oncology from fellow German company Vivoryon Therapeutics (until last month known as Probiodrug AG), which has already brought one of the compounds to Phase IIa for Alzheimer’s disease.

In return for the option, MorphoSys has committed to investing up to €15m in a minority stake in Vivoryon in a capital raise before the end of November 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

More from Anticancer

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).